Celgene Corporation Earnings: Trading Price for Volume

Celgene Corporation Earnings: Trading Price for Volume


Sales of top-selling Revlimid grew 20% year over year as doctors continue to increase the use of the drug and patients stay on it longer. Sales of Abraxane, which have been relatively stalled for awhile, rose 5% year over year with all of the growth coming from outside the U.S. The one issue came from Otezla, which produced sales growth of 24% year over year.



from Biotech News